Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety and effectiveness of nivolumab alone and in combination with ipilimumab in pediatric patients with high grade primary central nervous system (CNS) malignancies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03130959
Study type Interventional
Source Bristol-Myers Squibb
Contact
Status Completed
Phase Phase 2
Start date June 12, 2017
Completion date January 17, 2022

See also
  Status Clinical Trial Phase
Completed NCT02488759 - An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Phase 1/Phase 2
Terminated NCT01986218 - Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02387996 - A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer Phase 2
Active, not recruiting NCT02632409 - An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer Phase 3
Active, not recruiting NCT03143153 - A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Phase 3
Not yet recruiting NCT03138486 - A Study of the Effectiveness in Patients With Gastric or Gastroesophageal Junction Cancer With Nivolumab by Itself or in Combination With Ipilimumab and in Patients With Esophageal Cancer With Combination of Nivolumab and Ipilimumab. Phase 2